182 related articles for article (PubMed ID: 23688130)
1. CYP17A1: a biochemistry, chemistry, and clinical review.
Porubek D
Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
[TBL] [Abstract][Full Text] [Related]
2. Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals.
Peng Z; Xueb G; Chen W; Xia S
Environ Toxicol Pharmacol; 2019 Jul; 69():16-25. PubMed ID: 30921671
[TBL] [Abstract][Full Text] [Related]
3. Kinetic processivity of the two-step oxidations of progesterone and pregnenolone to androgens by human cytochrome P450 17A1.
Gonzalez E; Guengerich FP
J Biol Chem; 2017 Aug; 292(32):13168-13185. PubMed ID: 28684414
[TBL] [Abstract][Full Text] [Related]
4. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
5. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylation and lyase reactions of steroids catalyzed by mouse cytochrome P450 17A1 (Cyp17a1).
Lee SG; Kim V; Lee GH; Kim C; Jeong E; Guengerich FP; Kim D
J Inorg Biochem; 2023 Mar; 240():112085. PubMed ID: 36640554
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
8. Active site proton delivery and the lyase activity of human CYP17A1.
Khatri Y; Gregory MC; Grinkova YV; Denisov IG; Sligar SG
Biochem Biophys Res Commun; 2014 Jan; 443(1):179-84. PubMed ID: 24299954
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
10. Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Petrunak EM; DeVore NM; Porubsky PR; Scott EE
J Biol Chem; 2014 Nov; 289(47):32952-64. PubMed ID: 25301938
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
12. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Du JJ; Chen HL; Li YC
Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Andersen KL; Yadav R; Brixius-Anderko S; Scott EE; Olsen L; Jørgensen FS; Björkling F
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660148
[TBL] [Abstract][Full Text] [Related]
14. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the Clinically Relevant E305G Mutation in Human P450 CYP17A1.
Liu Y; Grinkova Y; Gregory MC; Denisov IG; Kincaid JR; Sligar SG
Biochemistry; 2021 Nov; 60(43):3262-3271. PubMed ID: 34662099
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the crucial intermediates in androgen production.
Mak PJ; Gregory MC; Denisov IG; Sligar SG; Kincaid JR
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15856-61. PubMed ID: 26668369
[TBL] [Abstract][Full Text] [Related]
18. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
19. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
Krug SJ; Hu Q; Hartmann RW
J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
[TBL] [Abstract][Full Text] [Related]
20. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
